Bristol-Myers Squibb Company (BMY) vs GSK plc (GSK)
A side-by-side comparison of Bristol-Myers Squibb Company and GSK plc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 11, 2026. Differences are shown without an overall score or investment verdict.
BMY
Bristol-Myers Squibb Company
$63.61HealthcareDelayed quote: Aug 11, 2026, 4:00 PM EDT
GSK
GSK plc
$50.90HealthcareDelayed quote: Aug 11, 2026, 4:00 PM EDT
Total return — BMY vs GSK
growth of $100 · dividends reinvested · last 10yBMY +58.3% (+4.7%/yr)GSK +88.1% (+6.5%/yr)GSK compounded faster over this window
BMY GSK
BMY vs GSK: by the numbers
- •BMY is the larger company ($129.94B vs $101.98B market cap).
- •BMY trades at the lower trailing earnings multiple (14.28 vs 16.49 P/E), one valuation lens rather than an overall verdict.
- •BMY converts more revenue to profit (18.87% vs 14.52% net margin).
- •BMY grew revenue faster over the past five years (2.08% vs 1.38% CAGR).
- •BMY pays the higher dividend yield (3.87% vs 3.44%).
Metrics side by side
Valuation
| Metric | BMY | GSK |
|---|---|---|
| P/E ratio | 14.28 | 16.49 |
| Forward P/E | 9.62 | 14.58 |
| P/S ratio | 2.70 | 2.39 |
| P/B ratio | 5.95 | 4.56 |
| EV / EBITDA | 9.87 | 8.46 |
| FCF yield | 8.61% | 8.80% |
Profitability
| Metric | BMY | GSK |
|---|---|---|
| Gross margin | 70.16% | 72.71% |
| Operating margin | 28.27% | 20.72% |
| Net margin | 18.87% | 14.52% |
| ROE | 41.59% | 27.67% |
| ROIC | 15.03% | 16.61% |
Dividends
| Metric | BMY | GSK |
|---|---|---|
| Dividend yield | 3.87% | 3.44% |
| Payout ratio | 72.54% | 47.32% |
Growth (annualized)
| Metric | BMY | GSK |
|---|---|---|
| Revenue CAGR (5Y) | 2.08% | 1.38% |
| EPS CAGR (5Y) | 9.38% | -0.71% |
| FCF CAGR (5Y) | -0.95% | -2.45% |
| Total return CAGR (5Y) | 3.38% | 9.56% |
Frequently asked
- Which has the lower trailing P/E, BMY or GSK?
- BMY has the lower trailing P/E: BMY trades at 14.28 and GSK at 16.49. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, BMY or GSK?
- Over the past five years, BMY grew revenue faster — BMY at a 2.08% CAGR versus GSK at 1.38%.
- Does BMY or GSK pay a bigger dividend?
- BMY yields 3.87% and GSK yields 3.44% based on trailing dividends and the latest price.
- Is BMY or GSK more profitable?
- BMY runs the higher net margin — BMY at 18.87% versus GSK at 14.52%.
- How have BMY and GSK total returns compared?
- Over the past 10 years, BMY delivered 4.30% and GSK delivered 6.47% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bristol-Myers Squibb P/E ratioGSK P/E ratioBristol-Myers Squibb dividend yieldGSK dividend yieldBristol-Myers Squibb ROEGSK ROEBristol-Myers Squibb operating marginGSK operating marginBristol-Myers Squibb revenue growthGSK revenue growthBristol-Myers Squibb free cash flowGSK free cash flow
Bristol-Myers Squibb & GSK appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 11, 2026.